Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension

Slide: 12 of 16

Evidence on Adverse Effects

Cough was more frequently observed as an adverse event in groups treated with ACEIs than in groups treated with ARBs. Withdrawals due to adverse events were modestly more frequent for groups receiving an ACEI rather than an ARB; this is consistent with differential rates of cough. No significant between-class differences were observed in the rates of any other commonly reported adverse events.

Note: When used during pregnancy, ACEIs, ARBs, and DRIs can injure or be fatal to the developing fetus.